IL277404A - C3-binding agents and methods of use thereof - Google Patents

C3-binding agents and methods of use thereof

Info

Publication number: IL277404A
Authority: IL; Israel
Prior art keywords: methods; binding agents; binding; agents
Prior art date: 2018-04-03

Application number

IL277404A

Other languages

Hebrew (he)

Original Assignee

Ngm Biopharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2018-04-03

Filing date

2020-09-16

Publication date

2020-11-30

2020-09-16 Application filed by Ngm Biopharmaceuticals Inc filed Critical Ngm Biopharmaceuticals Inc

2020-11-30 Publication of IL277404A publication Critical patent/IL277404A/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/624—Disulfide-stabilized antibody (dsFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Animal Behavior & Ethology (AREA)
Ophthalmology & Optometry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

IL277404A 2018-04-03 2020-09-16 C3-binding agents and methods of use thereof IL277404A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201862652253P	2018-04-03	2018-04-03
PCT/US2019/025123 WO2019195136A1 (en)	2018-04-03	2019-04-01	C3-binding agents and methods of use thereof

Publications (1)

Publication Number	Publication Date
IL277404A true IL277404A (en)	2020-11-30

Family

ID=66630340

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL277404A IL277404A (en)	2018-04-03	2020-09-16	C3-binding agents and methods of use thereof

Country Status (18)

Country	Link
US (3)	US11136381B2 (en)
EP (1)	EP3790897A1 (en)
JP (2)	JP7477457B2 (en)
KR (1)	KR20200138290A (en)
CN (1)	CN112105638A (en)
AR (1)	AR117565A1 (en)
AU (1)	AU2019248557A1 (en)
BR (1)	BR112020019907A2 (en)
CA (1)	CA3093356A1 (en)
CL (2)	CL2020002522A1 (en)
CO (1)	CO2020013468A2 (en)
IL (1)	IL277404A (en)
MX (1)	MX2020010323A (en)
PE (1)	PE20212132A1 (en)
PH (1)	PH12020500664A1 (en)
SG (1)	SG11202008897SA (en)
TW (1)	TWI833742B (en)
WO (1)	WO2019195136A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR117565A1 (en)	2018-04-03	2021-08-18	Ngm Biopharmaceuticals Inc	BINDING AGENTS TO C3 AND METHOD OF USE OF THE SAME
WO2021226442A2 (en) *	2020-05-08	2021-11-11	Ngm Biopharmaceuticals, Inc.	Therapeutic uses of c3-binding agents
EP4213808A4 (en) *	2020-09-21	2024-05-22	Apellis Pharmaceuticals, Inc.	Methods of treating eye disorders
US20230257455A1 (en)	2021-12-22	2023-08-17	Cdr-Life Ag	Anti-c3 antibodies and antigen-binding fragments thereof and their uses for treating eye or ocular diseases
WO2024086555A1 (en)	2022-10-17	2024-04-25	Ngm Biopharmaceuticals, Inc.	Uses of anti-c3 antibodies
CN117447601B (en) *	2023-12-22	2024-03-08	北京索莱宝科技有限公司	Antibodies to porcine IgM, antibody compositions and uses thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2000015259A1 (en) *	1998-09-10	2000-03-23	The University Of Virginia Patent Foundation	Antibodies to c3b(i) for delivery of diagnostic and therapeutic agents to cancer cells
WO2004031240A1 (en) *	2002-10-04	2004-04-15	Stichting Sanquin Bloedvoorziening	Monoclonal antibody anti-c3-2 directed against the third component of complement (c3) and its use in methods to inhibit complement activation
US7816497B2 (en)	2002-10-30	2010-10-19	University Of Kentucky	Compositions and methods for inhibiting drusen complement components C3a and C5a for the treatment of age-related macular degeneration
WO2004041867A2 (en) *	2002-11-08	2004-05-21	Ablynx N.V.	Camelidae antibodies against imminoglobulin e and use thereof for the treatment of allergic disorders
WO2006012621A2 (en)	2004-07-23	2006-02-02	University Of Virginia Patent Foundation	Compositions and methods for regulating the alternative pathway of complement
EP1853299A4 (en)	2005-01-14	2009-11-11	Univ California	COMPOSITIONS AND METHODS FOR INHIBITING DRUSEN FORMATION AND METHODS FOR DIAGNOSING OR TREATING DRUSEN RELATED PATHOLOGIES
US8168584B2 (en)	2005-10-08	2012-05-01	Potentia Pharmaceuticals, Inc.	Methods of treating age-related macular degeneration by compstatin and analogs thereof
BRPI0619657A2 (en)	2005-11-04	2011-11-08	Genentech Inc	methods of preventing or ameliorating eye disease, using a complement inhibitor, using a specific siren for a complement system protein and using a nucleic acid encoding a complement system inhibitor
US8580735B2 (en)	2007-02-05	2013-11-12	Apellis Pharmaceuticals, Inc.	Local complement inhibition for treatment of complement-mediated disorders
US8192742B2 (en)	2007-03-23	2012-06-05	NovelMed Therapeutics	Method of inhibiting complement activation with human anti-factor C3 antibodies and use thereof
US9745367B2 (en)	2007-03-23	2017-08-29	Novelmed Theraputics, Inc.	Alternative pathway specific antibodies for treating arthritis
CN101809034B (en)	2007-06-07	2015-07-08	健泰科生物技术公司	C3b antibodies and methods for the prevention and treatment of complement- associated disorders
US20100291106A1 (en)	2009-05-06	2010-11-18	Novartis Ag	Compositions and methods for antibodies targeting complement protein c3b
US8772449B2 (en)	2009-05-20	2014-07-08	Toray Industries, Inc.	Cell-penetrating peptides
US9291622B2 (en)	2009-05-21	2016-03-22	Apellis Pharmaceuticals, Inc.	Complement assays and uses thereof
US20130177567A1 (en)	2010-05-18	2013-07-11	Sydansk Universitet	Novel c3c epitope, antibodies binding thereto, and use thereof
KR20130036276A (en)	2010-06-22	2013-04-11	더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트	Antibodies to the c3d fragment of complement component 3
AU2013243574B2 (en)	2012-04-03	2017-12-07	Novelmed Therapeutics, Inc	Humanized and chimeric anti-factor C3 antibodies and uses thereof
JP2017502023A (en)	2013-12-24	2017-01-19	ノーベルメッドセラピューティクスインコーポレイテッド．	Compositions and methods for treating eye diseases
SG10202003996YA (en)	2014-05-05	2020-06-29	Regeneron Pharma	Humanized c5 and c3 animals
US10815276B2 (en)	2014-05-21	2020-10-27	Entrada Therapeutics, Inc.	Cell penetrating peptides and methods of making and using thereof
EP3229586A4 (en) *	2014-12-10	2018-10-24	Regents of the University of Minnesota	Genetically modified cells, tissues, and organs for treating disease
WO2017048466A1 (en)	2015-09-15	2017-03-23	The Regents Of The University Of California	Compositions and methods for delivering biotherapeutics
CN117503905A (en)	2015-10-07	2024-02-06	阿佩利斯制药有限公司	dosing regimen
RU2630647C1 (en) *	2016-05-27	2017-09-11	Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства	Humanized antibody to conformational c3 epitope constituent of human complement, dna sequence (versions), expression vector containing dna sequence (versions), and ovarian cells' strain of chinese hamster cho-humc34-producer of this humanized antibody
EP3654941A1 (en)	2017-07-17	2020-05-27	Keith Roizman	Topical delivery of therapeutic agents comprising cell-penetrating peptides for use for the treatment of age-related macular degeneration and other eye diseases
AR117565A1 (en)	2018-04-03	2021-08-18	Ngm Biopharmaceuticals Inc	BINDING AGENTS TO C3 AND METHOD OF USE OF THE SAME

2019
- 2019-04-01 AR ARP190100853A patent/AR117565A1/en unknown
- 2019-04-01 US US16/371,684 patent/US11136381B2/en active Active
- 2019-04-01 KR KR1020207030405A patent/KR20200138290A/en not_active Application Discontinuation
- 2019-04-01 CN CN201980027315.6A patent/CN112105638A/en active Pending
- 2019-04-01 SG SG11202008897SA patent/SG11202008897SA/en unknown
- 2019-04-01 BR BR112020019907-9A patent/BR112020019907A2/en unknown
- 2019-04-01 PE PE2020001505A patent/PE20212132A1/en unknown
- 2019-04-01 TW TW108111549A patent/TWI833742B/en active
- 2019-04-01 JP JP2020554097A patent/JP7477457B2/en active Active
- 2019-04-01 MX MX2020010323A patent/MX2020010323A/en unknown
- 2019-04-01 WO PCT/US2019/025123 patent/WO2019195136A1/en active Application Filing
- 2019-04-01 AU AU2019248557A patent/AU2019248557A1/en active Pending
- 2019-04-01 EP EP19725880.9A patent/EP3790897A1/en active Pending
- 2019-04-01 CA CA3093356A patent/CA3093356A1/en active Pending
2020
- 2020-09-16 IL IL277404A patent/IL277404A/en unknown
- 2020-09-29 CL CL2020002522A patent/CL2020002522A1/en unknown
- 2020-10-01 PH PH12020500664A patent/PH12020500664A1/en unknown
- 2020-10-26 CO CONC2020/0013468A patent/CO2020013468A2/en unknown
2021
- 2021-08-02 CL CL2021002039A patent/CL2021002039A1/en unknown
- 2021-08-19 US US17/406,991 patent/US11767359B2/en active Active
2023
- 2023-08-10 US US18/447,741 patent/US20230382985A1/en active Pending
2024
- 2024-02-13 JP JP2024019502A patent/JP2024056851A/en active Pending

Also Published As

Publication number	Publication date
CL2021002039A1 (en)	2022-04-01
CN112105638A (en)	2020-12-18
WO2019195136A1 (en)	2019-10-10
EP3790897A1 (en)	2021-03-17
US11767359B2 (en)	2023-09-26
US11136381B2 (en)	2021-10-05
BR112020019907A2 (en)	2021-01-05
JP7477457B2 (en)	2024-05-01
AU2019248557A1 (en)	2020-09-24
US20190322730A1 (en)	2019-10-24
JP2024056851A (en)	2024-04-23
US20220119508A1 (en)	2022-04-21
PH12020500664A1 (en)	2021-06-07
PE20212132A1 (en)	2021-11-05
CA3093356A1 (en)	2019-10-10
US20230382985A1 (en)	2023-11-30
RU2020135712A (en)	2022-05-04
TWI833742B (en)	2024-03-01
SG11202008897SA (en)	2020-10-29
JP2021520195A (en)	2021-08-19
KR20200138290A (en)	2020-12-09
MX2020010323A (en)	2021-01-08
CO2020013468A2 (en)	2020-11-10
AR117565A1 (en)	2021-08-18
TW202003559A (en)	2020-01-16
CL2020002522A1 (en)	2021-02-26

Publication	Publication Date	Title
IL271025A (en)	2020-01-30	Multibiotic agents and methods of using the same
IL276731A (en)	2020-09-30	Anti-cd73 antibodies and methods of use thereof
IL278821A (en)	2021-01-31	Anti-sirpa antibodies and methods of use thereof
IL277404A (en)	2020-11-30	C3-binding agents and methods of use thereof
IL289748A (en)	2022-03-01	Heterodimers and methods of use thereof
IL276687A (en)	2020-09-30	Trialkyne linking agents and methods of use
IL279475A (en)	2021-01-31	Ectonucleotidase inhibitors and methods of use thereof
IL270214A (en)	2020-01-30	Anti-sortilin antibodies and methods of use thereof
IL281438A (en)	2021-04-29	Pyridazinones and methods of use thereof
IL283387A (en)	2021-07-29	Diarylhydantoin compounds and methods of use thereof
IL279648A (en)	2021-03-01	Anti-sirp-beta1 antibodies and methods of use thereof
IL277212A (en)	2020-10-29	Anti-klk5 antibodies and methods of use
ZA202100780B (en)	2023-07-26	Bismuth-thiol compositions and methods of use
IL276135A (en)	2020-09-30	Compositions and methods of use
IL281866A (en)	2021-05-31	Devices and methods of introduction into the body and their use
IL283782A (en)	2021-07-29	Anellosomes and methods of use
IL283884A (en)	2021-07-29	Anti-il-36 antibodies and methods of use thereof
IL280338A (en)	2021-03-01	Anti-siglec-5 antibodies and methods of use thereof
EP3749691A4 (en)	2021-10-27	Angptl8-binding agents and methods of use thereof
IL276053A (en)	2020-08-31	Therapeutic-gard and method of use thereof
IL274433A (en)	2020-06-30	Fulvestrant formulations and methods of their use
IL283231A (en)	2021-07-29	Dpep-1 binding agents and methods of use
IL281865A (en)	2021-05-31	Insertion devices and methods of use thereof
IL284689A (en)	2021-08-31	Endoscopic device and methods of use thereof
GB201610176D0 (en)	2016-07-27	Imaging agents and methods of use